Oncogen Pharma products and prices in Pakistan
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer - oncology · Karachi · Pakistan
Karachi-based pharmaceutical manufacturer focused on oncology products and operating under DRAP Drug Manufacturing Licence 000960.
Oncogen Pharma products in Pakistan
Oncogen Pharma (Pvt) Limited has 21 medicine presentations registered in Pakistan under 9 brands, covering 9 generic medicines. Most of its products are in Oncology & immunology. Its brands with the most registered strengths and packs are Nilosigna (Nilotinib), Lemiryl (Lenalidomide), Pacnogen (Paclitaxel (albumin-bound nanoparticles)) and Doxetran (Doxorubicin). 21 products have an official DRAP price on MedInfoBase. See all 9 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Oncogen Pharma (Pvt.) Limited
- Company type
- Private pharmaceutical manufacturer - oncology
- Address
- WH-26 & WH-27-A3, Korangi Creek Industrial Park, Karachi, Pakistan
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 50%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Oncogen Pharma (Pvt) Limited is priced against the market
16 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Abytiga | Abiraterone acetate | 250 mg | Tablet | 120's | 118215 | PKR 202,094.93 | PKR 1,684.12/tablet | 🔒 Pharma Pro |
| Cisrenza | Cisplatin | 50 mg/50 mL | Injection | 50mlx1's | 135220 | PKR 1,247.00 | PKR 24.94/mL | No comparator |
| Doxetran | Doxorubicin | 10 mg/5 mL | Injection | 1's | 130730 | PKR 763.54 | PKR 763.54/vial/unit | 🔒 Pharma Pro |
| Doxetran | Doxorubicin | 50 mg/25 mL | Injection | 1's | 130731 | PKR 2,630.76 | PKR 2,630.76/vial/unit | 🔒 Pharma Pro |
| Doxiant | Docetaxel | 20 mg | Concentrate for solution for infusion | 1's | 128122 | PKR 12,826.25 | PKR 12,826.25/vial/unit | No comparator |
| Doxiant | Docetaxel | 80 mg/4 mL | Concentrate for solution for infusion | 1's | 128123 | PKR 31,598.91 | PKR 31,598.91/vial/unit | 🔒 Pharma Pro |
| Imatigliv | Imatinib | 100 mg | Tablet | 60's | 118049 | PKR 72,284.27 | PKR 1,204.74/tablet | 🔒 Pharma Pro |
| Imatigliv | Imatinib | 400 mg | Tablet | 30's | 123414 | PKR 103,263.24 | PKR 3,442.11/tablet | 🔒 Pharma Pro |
| Lemiryl | Lenalidomide | 5 mg | Capsule | 21's | 120131 | PKR 7,014.71 | PKR 334.03/capsule | 🔒 Pharma Pro |
| Lemiryl | Lenalidomide | 10 mg | Capsule | 21's | 120132 | PKR 12,322.35 | PKR 586.78/capsule | 🔒 Pharma Pro |
| Lemiryl | Lenalidomide | 25 mg | Capsule | 21's | 120133 | PKR 27,142.76 | PKR 1,292.51/capsule | 🔒 Pharma Pro |
| Nilosigna | Nilotinib | 150 mg | Capsule | 40's | 118047 | PKR 64,212.89 | PKR 1,605.32/capsule | 🔒 Pharma Pro |
| Nilosigna | Nilotinib | 150 mg | Capsule | 112's | 118047 | PKR 267,584.86 | PKR 2,389.15/capsule | 🔒 Pharma Pro |
| Nilosigna | Nilotinib | 150 mg | Capsule | 120's | 118047 | PKR 286,698.49 | PKR 2,389.15/capsule | 🔒 Pharma Pro |
| Nilosigna | Nilotinib | 200 mg | Capsule | 28's | 118048 | PKR 59,931.16 | PKR 2,140.40/capsule | 🔒 Pharma Pro |
| Nilosigna | Nilotinib | 200 mg | Capsule | 112's | 118048 | PKR 356,780.47 | PKR 3,185.54/capsule | 🔒 Pharma Pro |
| Onkivia Tablet 200mgRegistry verified | Ribociclib as Succinate | — | — | — | 135051Official source ↗ | No indexed price | — | — |
| Pacnogen | Paclitaxel (albumin-bound nanoparticles) | 300 mg/50 mL | Concentrate for solution for infusion | 1's | 128119 | PKR 40,541.44 | PKR 40,541.44/vial/unit | No comparator |
| Pacnogen | Paclitaxel (albumin-bound nanoparticles) | 30 mg/5 mL | Concentrate for solution for infusion | 1's | 128120 | PKR 5,823.22 | PKR 5,823.22/vial/unit | No comparator |
| Pacnogen | Paclitaxel (albumin-bound nanoparticles) | 150 mg/25 mL | Concentrate for solution for infusion | 1's | 128121 | PKR 25,196.23 | PKR 25,196.23/vial/unit | No comparator |
| Pectibine | Capecitabine | 500 mg | Tablet | 120's | 118214 | PKR 43,886.88 | PKR 365.72/tablet | 🔒 Pharma Pro |
| Pectibine | Capecitabine | 500 mg | Tablet | 10's | 118214 | PKR 4,262.71 | PKR 426.27/tablet | 🔒 Pharma Pro |
| Platigen Injection 150mg/15ml (IV)Registry verified | Carboplatin | — | — | — | 134865Official source ↗ | No indexed price | — | — |
| Platigen Injection 450mg/45ml (IV)Registry verified | Carboplatin | — | — | — | 134866Official source ↗ | No indexed price | — | — |
All 9 Oncogen Pharma brands in Pakistan
- Abytiga Abiraterone acetate · 250 mg tablet
- Cisrenza Cisplatin · 50 mg/50 mL injection
- Doxetran Doxorubicin · 10 mg/5 mL injection, 50 mg/25 mL injection
- Doxiant Docetaxel · 20 mg infusion, 80 mg/4 mL infusion
- Imatigliv Imatinib · 100 mg tablet, 400 mg tablet
- Lemiryl Lenalidomide · 10 mg capsule, 25 mg capsule, 5 mg capsule
- Nilosigna Nilotinib · 150 mg capsule, 200 mg capsule
- Pacnogen Paclitaxel (albumin-bound nanoparticles) · 150 mg/25 mL infusion, 30 mg/5 mL infusion, 300 mg/50 mL infusion
- Pectibine Capecitabine · 500 mg tablet
Oncogen Pharma: common questions
How many products does Oncogen Pharma have in Pakistan?
Oncogen Pharma (Pvt) Limited has 21 registered medicine presentations in Pakistan, sold under 9 brands and covering 9 generic medicines.
What are the main brands of Oncogen Pharma?
By number of registered strengths and packs, its largest brands are Nilosigna (Nilotinib), Lemiryl (Lenalidomide), Pacnogen (Paclitaxel (albumin-bound nanoparticles)), Doxetran (Doxorubicin) and Doxiant (Docetaxel). This is not a sales ranking.
Which therapy areas does Oncogen Pharma cover?
The most products are in Oncology & immunology (21).
Where can I see Oncogen Pharma medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.